Alder Biopharmaceuticals Inc buy stratec
Start price
06.11.18
/
50%
€12.72
Target price
04.11.21
€25.26
Performance (%)
32.88%
End price
05.11.21
-
Summary
This prediction is currently being closed. With a performance of 32.88% the BUY prediction by stratec is a big success. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alder Biopharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | -0.268% | 5.471% | 14.271% | 19.027% |
| iShares Nasdaq 100 | 1.854% | 7.851% | 35.426% | 58.415% |
| iShares Nikkei 225® | 0.284% | 1.729% | 9.943% | 7.045% |
| iShares S&P 500 | 1.178% | 5.269% | 27.989% | 49.400% |
Comments by stratec for this prediction
In the thread Alder Biopharmaceuticals Inc diskutieren
Alder auf dem Weg, eine Best-in-Class-Therapie gegen Migräne zu entwickeln.
Eptinezumab wird derzeit in mehreren globalen, randomisierten, zulassungsrelevanten Phase-3-Studien untersucht, um seine Wirksamkeit und Sicherheit in der Migräneprävention zu bewerten. Bislang wurden mehr als 3.100 Patienten in das klinische Entwicklungsprogramm aufgenommen.
H. Lundbeck A/S (OTC:HLUKF) has agreed to acquire Alder BioPharmaceuticals (NASDAQ:ALDR) for $18 per share in cash plus one non-tradeable Contingent Value Right (CVR) for an additional $2 per share if migraine med eptinezumab is approved by the European Medicines Agency (EMA). The total value of the transaction is up to $1.95B.
In the thread Trading Alder Biopharmaceuticals Inc
Die von stratec gewählte maximale Laufzeit wurde überschritten